Floatz logo

Recombinant Wt1 Antigen-Specific Cancer Immunotherapeutic

Leukaemia, Myelocytic, Acute

Jules Bordet InstitutevaccinePhase 1/2Dormant
B
60/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
95/ 100

Competitive context

685 Active assets in the Leukaemia, Myelocytic, Acute cohort.

Asset / SponsorPhaseRating
Gemtuzumab
M.D. Anderson Cancer Center
Phase 4A
Cytosin-Arabinosid
Institute of Hematology & Blood Diseases Hospital, China
Phase 3BBB
AMSACRINE
University Hospital, Toulouse
Phase 4BBB
Posaconazole
AstraZeneca
Phase 4BBB
(+)-VINCRISTINE
Janssen Research & Development, LLC
Phase 3BBB

View all 50 →

Same molecule, other indications

Recombinant Wt1 Antigen-Specific Cancer Immunotherapeutic is also rated in:

Effects of ImmunotherapyDormant
CCC
Indicative ·
48 / 100
View asset →
acute myeloid leukemiaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →